The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.

ML.NET is a cross-platform open-source machine learning (ML) framework for .NET. ML.NET allows developers to easily build, train, deploy, and consume custom models in their .NET applications without ...

The two products, both manufactured by Amgen, are aflibercept biosimilars Pavblu and Skojoy. Both biosimilars are indicated ...

The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...

Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, ...

The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.

First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old.The virus-like particle (VLP) single-dose chikungunya vaccine is expected to launch in key European markets in ...

JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...

Group sales grew by 7%1 at constant exchange rates (CER; 3% in CHF), driven by strong demand for both medicines and diagnostics.Excluding COVID-19, Group sales increased by 9%.

KSHB002, a 125 mg/mL pre-filled syringe injection ... “We are thrilled with the results of our Phase 1 study and are excited to move forward with our global Phase 3 efficacy and safety trial.

The biosimilar's safety and immunogenicity profiles were found to be comparable to those of the reference product in the ...